Summary
46 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 21% a year over 5 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $318.3M.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.62%
- Raised in a row
- 1 year
You receive $0.89 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $62.38 is 31% above today's price. 89% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Management And Advisory Fees, Net 46%
- Carried Interest Allocation 36%
- Incentive Fees 11%
- Legacy Carried Interest Allocation 7.0%
By region
- UNITED STATES 54%
- Non-US 46%
Management And Advisory Fees, Net brings in 46% of revenue. Incentive Fees grew fastest, by 109% a year.
Segments in detail